NetworkNewsBreaks – INmune Bio, Inc. (NASDAQ: IN
Post# of 33
(Total Views: 230)
Posted On: 08/08/2019 3:38:13 PM
NetworkNewsBreaks – INmune Bio, Inc. (NASDAQ: INMB) Names Biotechnology Executive as New Board Member
INmune Bio (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that Edgardo “Ed” Baracchini, Ph.D., has joined its board of directors. Per the update, Dr. Baracchini’s impressive biotech business development background includes more than 25 years of experience in structuring and negotiating research and development partnerships, mergers, acquisitions and licensing agreements. He has negotiated over 80 business transactions, valued in excess of $5.3 billion, with multinational pharmaceutical firms, biotechnology companies and prominent universities. “Ed is a fantastic addition to our board of directors,” INmune Bio’s Chief Executive Officer and Chief Medical Officer RJ Tesi, MD, said in the news release. “He brings extensive business development and deal-making experience to the company, which is a critical skill set, as we continue to advance our three drug candidates through clinical trials.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
INmune Bio (NASDAQ: INMB), an immunology company focused on developing treatments that harness the patient’s innate immune system to fight disease, today announced that Edgardo “Ed” Baracchini, Ph.D., has joined its board of directors. Per the update, Dr. Baracchini’s impressive biotech business development background includes more than 25 years of experience in structuring and negotiating research and development partnerships, mergers, acquisitions and licensing agreements. He has negotiated over 80 business transactions, valued in excess of $5.3 billion, with multinational pharmaceutical firms, biotechnology companies and prominent universities. “Ed is a fantastic addition to our board of directors,” INmune Bio’s Chief Executive Officer and Chief Medical Officer RJ Tesi, MD, said in the news release. “He brings extensive business development and deal-making experience to the company, which is a critical skill set, as we continue to advance our three drug candidates through clinical trials.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)